{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:41:01Z","timestamp":1784191261146,"version":"3.55.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The objective of this study was to evaluate the in vitro antimicrobial activity of ceftaroline and comparator agents tested against Staphylococcus aureus isolates causing bloodstream infection (BSI).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 4426 S. aureus isolates from patients with BSI were collected in 150 medical centres in the USA in 2009\u201313 and tested for susceptibility to ceftaroline and comparators by the CLSI broth microdilution method.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 45.5% of isolates were MRSA. Ceftaroline (MIC50\/90, 0.25\/1 mg\/L) was active against 97.9% of S. aureus isolates at \u22641 mg\/L (highest MIC, 2 mg\/L). Daptomycin (MIC50\/90, 0.25\/0.5 mg\/L), linezolid (MIC50\/90, 1\/2 mg\/L) and vancomycin (MIC50\/90, 1\/1 mg\/L) were active against \u226599.8% of isolates at the respective susceptible breakpoints. Susceptibility rates for clindamycin (MIC50\/90, \u22640.25\/&amp;gt;2 mg\/L) and levofloxacin (MIC50\/90, \u22640.5\/&amp;gt;4 mg\/L) were 80.8% and 59.2%, respectively. Against MSSA, ceftaroline (MIC50\/90, 0.25\/0.25 mg\/L; 100.0% susceptible) was 16-, 4\u20138- and 4-fold more active in vitro (based on MIC50\/90) than ceftriaxone (MIC50\/90, 4\/4 mg\/L), linezolid (MIC50\/90, 1\/2 mg\/L) and vancomycin (MIC50\/90, 1\/1 mg\/L), respectively, and slightly more potent than daptomycin (MIC50\/90, 0.25\/0.5 mg\/L). When tested against MRSA, ceftaroline was active against 95.4% and 100.0% of isolates at \u22641 and \u22642 mg\/L, respectively. Moreover, ceftaroline retained significant activity against S. aureus with reduced susceptibility to vancomycin, daptomycin, clindamycin, levofloxacin and trimethoprim\/sulfamethoxazole.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Ceftaroline demonstrated potent in vitro activity when tested against a large collection of contemporary (2009\u201313) S. aureus isolates causing BSI in US hospitals.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkv076","type":"journal-article","created":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T19:31:30Z","timestamp":1427484690000},"page":"2053-2056","source":"Crossref","is-referenced-by-count":27,"title":["Activity of ceftaroline and comparator agents tested against <i>Staphylococcus aureus<\/i> from patients with bloodstream infections in US medical centres (2009\u201313)"],"prefix":"10.1093","volume":"70","author":[{"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Farrell","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,3,25]]},"reference":[{"key":"2022020121030760800_DKV076C1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccc.2013.03.008","article-title":"Staphylococcus aureus bacteremia, risk factors, complications, and management","volume":"29","author":"Keynan","year":"2013","journal-title":"Crit Care Clin"},{"key":"2022020121030760800_DKV076C2"},{"key":"2022020121030760800_DKV076C3"},{"key":"2022020121030760800_DKV076C4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/655827","article-title":"Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection","volume":"51","author":"Corey","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2022020121030760800_DKV076C5","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/657313","article-title":"Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia","volume":"51","author":"File","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2022020121030760800_DKV076C6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.clinmicnews.2013.10.001","article-title":"Left ventricular assist device endocarditis caused by vancomycin-intermediate Staphylococcus aureus successfully treated with ceftaroline: a review of the clinical case and overview of vancomycin resistance in Staphylococcus aureus","volume":"35","author":"Beydoun","year":"2013","journal-title":"Clin Microbiol Newsl"},{"key":"2022020121030760800_DKV076C7","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/jac\/dks006","article-title":"Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy","volume":"67","author":"Ho","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2022020121030760800_DKV076C8","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jac\/dkt009","article-title":"Ceftaroline in the treatment of concomitant methicillin-resistant and daptomycin-non-susceptible Staphylococcus aureus infective endocarditis and osteomyelitis: case report","volume":"68","author":"Jongsma","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2022020121030760800_DKV076C9","first-page":"219","article-title":"Ceftaroline for the treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus","volume":"23","author":"Pagani","year":"2014","journal-title":"J Heart Valve Dis"},{"key":"2022020121030760800_DKV076C10","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ijantimicag.2013.07.005","article-title":"Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature","volume":"42","author":"Polenakovik","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2022020121030760800_DKV076C11","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin Ther"},{"key":"2022020121030760800_DKV076C12","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1128\/AAC.00797-12","article-title":"Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity","volume":"56","author":"Rose","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020121030760800_DKV076C13","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/jac\/dku085","article-title":"Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study","volume":"69","author":"Tattevin","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2022020121030760800_DKV076C14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/IPC.0000000000000191","article-title":"Ceftaroline fosamil for the treatment of Staphylococcus aureus bacteremia secondary to acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia","volume":"23","author":"Vazquez","year":"2015","journal-title":"Infect Dis Clin Pract (Baltim Md)"},{"key":"2022020121030760800_DKV076C15","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jac\/dku455","article-title":"Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia","volume":"70","author":"Espedido","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2022020121030760800_DKV076C16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ijantimicag.2014.07.024","article-title":"Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations","volume":"44","author":"Paladino","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2022020121030760800_DKV076C17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/jac\/dku322","article-title":"Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia","volume":"70","author":"Barber","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"2022020121030760800_DKV076C18","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1093\/cid\/cis560","article-title":"Activity analyses of staphylococcal isolates from pediatric, adult and elderly patients; AWARE ceftaroline surveillance program","volume":"55","author":"Sader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2022020121030760800_DKV076C19","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically\u2014Ninth Edition: Approved Standard M07-A9","author":"Clinical and Laboratory Standards Institute","year":"2012"},{"key":"2022020121030760800_DKV076C20","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing: Twenty-fourth Informational Supplement M100-S24","author":"Clinical and Laboratory Standards Institute","year":"2014"},{"key":"2022020121030760800_DKV076C21","volume-title":"Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 4.0, January 2014","author":"EUCAST"},{"key":"2022020121030760800_DKV076C22","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1093\/jac\/dku114","article-title":"Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective","volume":"69","author":"Alm","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 4","key":"2022020121030760800_DKV076C23","first-page":"iv33","article-title":"Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity","volume":"65","author":"Drusano","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2022020121030760800_DKV076C24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/cid\/ciq067","article-title":"Antimicrobial resistance: not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA\u2014its evolving antimicrobial resistance and implications for therapy","volume":"52","author":"Chua","year":"2011","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/70\/7\/2053\/42355473\/jac_70_7_2053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/70\/7\/2053\/42355473\/jac_70_7_2053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T21:24:34Z","timestamp":1643750674000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/70\/7\/2053\/777083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,25]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,3,25]]},"published-print":{"date-parts":[[2015,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkv076","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,7]]},"published":{"date-parts":[[2015,3,25]]}}}